他克莫司治疗肾病综合征临床疗效及其对T淋巴细胞亚群影响研究

目的 探讨他克莫司治疗肾病综合征临床疗效及其对T淋巴细胞亚群影响.方法 选取2017年12月-2019年12月邢台市人民医院收治的肾病综合征患者105例作为研究对象,按随机数字表法将其分为观察组(n=54)与对照组(n=51),对照组予以泼尼松片治疗,观察组予以他克莫司治疗.对比2组临床治疗效果、T淋巴细胞亚群、肾功能...

Clinical Efficacy of Tacrolimus in the Treatment of Nephrotic Syndrome and Its Influence on T Lymphocyte Subsets

OBJECTIVE To explore the clinical effect of tacrolimus on nephrotic syndrome and its influence on T lymphocyte subsets. METHODS A total of 105 patients with nephrotic syndrome admitted to Xingtai People''s Hospital from December 2017 to December 2019 were selected as study subjects, and were divided into observation group(n=54) and control group(n=51) according to the random number table method. The control group was treated with prednisone tablet, while the observation group was treated with tacrolimus. The clinical treatment effect, T lymphocyte subsets, renal function indicators serum creatinine(Scr), blood urea nitrogen(BUN), serum albumin(ALB), 24 h urinary protein quantitative, serum triacylglycerol(TG), total cholesterol(TC), plasma fibrinogen(FIB), blood viscosity(PV) and adverse reactions were compared between the two groups. RESULTS After treatment, the total clinical effective rate of the observation group was significantly higher than that of the control group(87.04% vs 68.63%)(P<0.05). The levels of CD4⁺ and CD4⁺/CD8⁺ in the observation group were significantly higher than those before treatment and the control group, and CD8⁺ was significantly lower than that in the control group(P&llt;0.05). In the observation group, serum ALB was significantly higher than that before treatment and control group, while urinary protein quantification, Scr, BUN levels were significantly lower than that before treatment and control group(P<0.05). The levels of TG, TC, FIB and PV in the observation group were significantly higher than those in the control group(P<0.05). The total adverse reaction rate in the observation group was significantly lower than that in the control group (5.56% vs 19.61%)(P<0.05). CONCLUSION Tacrolimus treatment in patients with nephrotic syndrome can not only significantly improve the clinical efficacy, but also improve the level of T lymphocyte CD4⁺, CD8⁺, CD4⁺/CD8⁺ cells and blood lipid-related levels. It is safe, beneficial to the recovery of renal function and has high clinical value.